Aarti Industries Ltd. makes a corporate announcement

The contract runs through 31 March 2030, implying an expected duration of approximately four years from the March 2026 announcement; the exact contractual start date was not separately disclosed ^[1].

• Total contract value: approximately USD 150 million over the contract period ^[1]
• Derived annualized revenue: approximately USD 37.5 million per year (USD 150 million ÷ four years)
• FY24 Specialty Chemicals segment revenue: Rs 600 Crores ^[2]

A precise percentage contribution cannot be calculated because the contract value is reported in USD while FY24 segment revenue is reported in INR, and no exchange rate is specified. The comparison is therefore USD 37.5 million annualized versus Rs 600 Crores of FY24 Specialty Chemicals revenue.

The USD 150 million contract does not require incremental capital expenditure, according to Aarti Industries. Management stated that the company has adequate existing capacity and will fulfil the agreement by increasing utilisation of already-created manufacturing assets; the contract runs through 31 March 2030. ^{[3] [1]}

The key distinction is:

• USD 150 million agrochemical intermediate contract: serviced through existing capacity, with no contract-specific incremental capex. ^[1]
• Previously disclosed capex projects: Zone IV, PEDA, DCB debottlenecking, Augene/Superform and other initiatives are broader growth projects. Management has not said that the USD 150 million contract depends on their commissioning. The company’s earlier commentary instead linked the contract to products for which capacities had already been created. ^[4]
• Separate backward-integration contract: this is a different agreement and does involve approximately Rs 200-250 Crores of capex over the residual 15-year contract period. ^[3]

Implication: the contract should be relatively capital-light at the plant level and could improve utilisation and operating leverage on existing assets. However, “no incremental capex” does not mean zero incremental funding: higher production may still require additional raw-material inventory and receivables, particularly given the company’s recent working-capital expansion associated with higher feedstock prices and exports. ^[5]

The disclosure does not quantify the specific spare capacity available, utilisation uplift, or working-capital requirement attributable to this contract.